NasdaqGM:XNCRBiotechs
What Xencor (XNCR)'s 2026 XmAb Pivotal Plans and Cash Runway Through 2028 Mean For Shareholders
Xencor recently outlined its 2026 priorities and advancement milestones for its clinical-stage XmAb drug portfolio, highlighting progress across oncology and autoimmune programs, including early anti-tumor activity and tolerability for its lead T-cell engagers.
An important takeaway for investors is Xencor’s expectation that its current cash resources should fund research and operations through 2028, supporting multiple planned pivotal studies without near-term financing guidance.
We’ll now...